Skip to main content
Fig. 5 | BMC Cancer

Fig. 5

From: Prediction of anti-CD25 and 5-FU treatments efficacy for pancreatic cancer using a mathematical model

Fig. 5

Comparison treatment efficacies and Analysis of interactions among treatments. The overall efficacy of 5-FU treatment, anti-CD25 treatment, and combination therapy was plotted as the percentage of tumor growth inhibition using instantaneous tumor size (first panel of Fig. 5. A, B, C, and D) and average tumor size (second panel of Figs. 5. A, B, C, and D) as outcomes. The blue lines represent the inhibition percentage of tumor growth under 5-FU treatment on a specified time setting in each subplot that is calculated based on the instantaneous tumor size during time and the red lines under anti-CD25 treatment and yellow lines under combination therapy. (Third panel of Fig. 5. A, B, C, and D) The Bliss combination index (CI) for 5-FU and Anti-CD25 treatments combination using instantaneous tumor size (CI inst) and average tumor size (CI ave) as outcome shows the synergistic interaction of treatments

Back to article page